文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

皮下伊维菌素联合锌治疗中年中度COVID-19患者的抗新冠特性:随机对照试验研究方案的结构化摘要

Anti-COVID property of subcutaneous ivermectin in synergy with zinc among midlife moderately symptomatic patients: a structured summary of a study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2021-09-06

该研究为四盲、安慰剂对照、多臂多中心随机优效性试验,计划纳入180例中年中度COVID-19症状且SARS-CoV-2 PCR阳性的患者,随机分配至6组(每组30例),比较皮下或口服伊维菌素联合或不联合锌的临床与影像学改善。主要终点为症状持续时间、SARS-CoV-2清除率、HRCT胸部评分和临床分级量表(第6天),30天死亡率为次要终点。

要点

  • 四盲安慰剂对照多臂试验,比较伊维菌素(皮下/口服)联合或不联合锌治疗中度COVID-19。
  • 主要终点包括症状持续时间、病毒清除、HRCT评分和临床分级量表(第6天)。
  • 计划随机180例,6组每组30例,1:1:1:1:1:1分配。

核心结论

  • 该研究旨在量化伊维菌素(皮下/口服)联合或不联合锌对中度COVID-19患者临床和影像学改善的有效性。

研究设计与样本

  • 四盲、安慰剂对照、多臂多中心随机优效性试验,计划随机180例中年中度COVID-19患者,每组30例。
  • 随机化采用简单抽签法,按1:1:1:1:1:1比例分配至6组,患者、初级保健医生、结局评估者和数据收集团队均设盲。

关键数值与推荐

  • 干预措施:A组皮下IVM 200 μg/kg/48 h;B组皮下IVM 200 μg/kg/48 h联合口服锌20mg/8 h;C组口服IVM 0.2 mg/kg/day;D组口服IVM 0.2 mg/kg/day联合口服锌20mg/8 h;E组仅口服锌20mg/8 h;X组安慰剂。所有组均接受标准治疗和相应安慰剂。
  • 主要终点:症状持续时间、SARS-CoV-2清除率(第7天第二次PCR)、HRCT胸部评分(第6天,最高25分)和临床分级量表(第6天,7分制)。
  • 次要终点:30天死亡率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The study objective is to quantify the effectiveness of ivermectin (subcutaneous/oral IVM) in the presence or absence of zinc (Zn) for clinical and radiological improvement in coronavirus disease 2019 (COVID-19) patients with moderate severity. TRIAL DESIGN: This quadruple-blinded, placebo-controlled randomized clinical trial will be a multiarmed multi-centered study with superiority framework. PARTICIPANTS: Quinquagenarian and sexagenarian patients with moderate COVID-19 symptoms and positive severe respiratory syndrome coronavirus -2 (SARS-CoV-2) PCR will be included. Participants with co-morbidities and pregnant women will be excluded. Patient recruitment will be done in Shaikh Zayed Medical Complex, Doctors Lounge and Ali Clinic in Lahore (Pakistan). INTERVENTION AND COMPARATOR: The registered patients will be allocated in 6 groups (30 participants each). Patients will be taking subcutaneous IVM at 200 μg/kg/48 h (Arm A) or subcutaneous IVM at 200 μg/kg/48 h and oral Zn 20mg/8 h (Arm B) or oral IVM at 0.2 mg/kg/day (Arm C) or oral IVM at 0.2 mg/kg/day and oral Zn 20mg/8 h (Arm D) or alone oral Zn 20mg/8 h (Arm E) or placebo alone (Arm X). Patients in all arms will receive standard care and respective placebo (empty capsule 8 hourly and/or subcutaneous normal saline 2ml/48 h). MAIN OUTCOMES: Primary endpoints will be duration of symptomatic phase and SARS-CoV-2 clearance along with high resolution CT (HRCT) chest score and clinical grade scale (CGS) on day 6. 30-day mortality will be documented as a secondary endpoint. SARS-CoV-2 clearance will be calculated by second PCR on day 7. HRCT chest score will be measured by the percentage and lung lobes involvement on day 6 with a maximum score of 25. CGS will be recorded on a seven-point scale; grade 1 (not hospitalized, no evidence of infection and resumption of normal activities), grade 2 (not hospitalized, but unable to resume normal activities), grade 3 (hospitalized, not requiring supplemental oxygen), grade 4 (hospitalized, requiring supplemental oxygen), grade 5 (hospitalized, requiring nasal high-flow oxygen therapy and/or noninvasive mechanical ventilation), grade 6 (hospitalized, requiring ECMO and/or invasive mechanical ventilation) and grade 7 (death). RANDOMISATION: A simple lottery method will be used to randomly allocate scrutinized patients in 1:1:1:1:1:1 ratio in 6 groups. BLINDING (MASKING): Patients, primary care physicians, outcome assessors and the data collection team will be blinded. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): 180 participants will be randomized into six arms with five investigational and one placebo group. TRIAL STATUS: Institutional Review Board Shaikh Zayed Post-Graduate Medical Complex, Lahore, Pakistan has approved the protocol (version 2.3) with ID SZMC/IRB/Internal0056/2020. The trial was approved on July 14, 2020, and enrolment started on July 30, 2020. The estimated completion date is October 30, 2021. TRIAL REGISTRATION: Clinical Trial has been retrospectively registered on www.clinicaltrials.gov with registration ID NCT04472585 dated July 16, 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). With the intention of expediting dissemination of this trial, the conventional formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ashraf S, Ashraf S, Farooq I, et al. Anti-COVID property of subcutaneous ivermectin in synergy with zinc among midlife moderately symptomatic patients: a structured summary of a study protocol for a randomised controlled trial. Trials. 2021. PMID: 34488858. doi:10.1186/s13063-021-05487-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。